Double maintains 1 strategies that include QURE - uniQure NV
Current Value
$14.131 Year Return
Current Value
$14.131 Year Return
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| YEXT | -19.57% | $1.02B | +59.13% | 0.00% |
| AMT | -16.64% | $105.08B | +16.75% | 2.96% |
| HELE | -15.52% | $713.22M | -65.98% | 0.00% |
| CRVO | -15.12% | $51.61M | -62.59% | 0.00% |
| HSY | -11.38% | $35.62B | -4.79% | 3.11% |
| SBAC | -11.23% | $25.65B | +26.32% | 1.76% |
| COR | -11.03% | $57.24B | +32.73% | 0.74% |
| MDB | -10.88% | $16.84B | -20.72% | 0.00% |
| CBOE | -10.79% | $24.29B | +35.36% | 1.09% |
| ASPS | -10.66% | $99.18M | -12.89% | 0.00% |
| FIZZ | -9.97% | $4.21B | -14.80% | 0.00% |
| TBRG | -9.79% | $352.75M | +121.93% | 0.00% |
| AGL | -9.47% | $985.21M | -59.52% | 0.00% |
| OSCR | -9.16% | $5.21B | +23.27% | 0.00% |
| NOAH | -8.95% | $813.45M | +31.55% | 8.67% |
| CARV | -8.81% | $8.73M | +25.55% | 0.00% |
| CNP | -8.73% | $23.84B | +19.89% | 2.34% |
| ED | -8.18% | $36.31B | +13.27% | 3.35% |
| MMC | -7.89% | $107.33B | +2.75% | 1.52% |
| AEP | -7.87% | $55.76B | +19.14% | 3.55% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| SUSC | -0.03% | $1.16B | 0.18% |
| BNO | 0.03% | $103.86M | 1% |
| IBTF | 0.08% | $2.02B | 0.07% |
| MINO | 0.08% | $319.43M | 0.39% |
| IBMN | 0.11% | $446.95M | 0.18% |
| PDBC | -0.15% | $4.44B | 0.59% |
| IGLB | 0.18% | $2.36B | 0.04% |
| DBC | 0.27% | $1.22B | 0.87% |
| SGOV | 0.27% | $49.73B | 0.09% |
| MSOS | -0.29% | $296.62M | 0.77% |
| FUTY | 0.30% | $1.82B | 0.084% |
| SPBO | -0.31% | $1.62B | 0.03% |
| BCI | -0.33% | $1.59B | 0.26% |
| GLTR | 0.36% | $1.43B | 0.6% |
| VCLT | -0.36% | $9.90B | 0.04% |
| CMDY | -0.39% | $269.01M | 0.28% |
| XLU | 0.40% | $18.93B | 0.09% |
| IBMP | 0.41% | $553.36M | 0.18% |
| VUSB | 0.42% | $5.35B | 0.1% |
| USFR | -0.42% | $18.59B | 0.15% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| OGS | 0.01% | $4.36B | +13.67% | 3.68% |
| SPB | 0.01% | $1.36B | -36.51% | 3.32% |
| EXAS | 0.02% | $10.30B | +26.48% | 0.00% |
| AEE | 0.02% | $26.67B | +34.81% | 2.88% |
| THG | 0.03% | $6.01B | +32.11% | 2.15% |
| LMT | 0.03% | $109.17B | +0.05% | 2.81% |
| ARLP | 0.05% | $3.32B | +2.62% | 10.80% |
| KNSL | 0.05% | $11.18B | +25.68% | 0.13% |
| HIG | -0.06% | $35.97B | +26.56% | 1.63% |
| SG | -0.07% | $1.71B | -47.98% | 0.00% |
| RGLD | -0.08% | $11.69B | +40.58% | 0.95% |
| UHS | 0.08% | $12.18B | +2.28% | 0.44% |
| RSKD | -0.08% | $812.14M | -22.36% | 0.00% |
| NIU | -0.08% | $238.35M | +93.22% | 0.00% |
| DGX | 0.08% | $20.02B | +31.24% | 1.73% |
| GPN | -0.08% | $19.99B | -15.57% | 1.23% |
| SYPR | 0.09% | $46.42M | +9.19% | 0.00% |
| NHTC | 0.09% | $51.35M | -35.08% | 17.78% |
| UPWK | 0.10% | $1.78B | +25.88% | 0.00% |
| STE | -0.10% | $23.87B | +11.14% | 0.95% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TAIL | -18.14% | $99.49M | 0.59% |
| VIXY | -16.02% | $165.58M | 0.85% |
| SPTS | -15.21% | $5.77B | 0.03% |
| BTAL | -14.85% | $295.67M | 1.43% |
| IVOL | -14.17% | $348.25M | 1.02% |
| FXY | -14.09% | $820.31M | 0.4% |
| XONE | -13.87% | $585.85M | 0.03% |
| IBTI | -13.79% | $1.06B | 0.07% |
| UTWO | -13.01% | $379.27M | 0.15% |
| SCHO | -12.83% | $11.46B | 0.03% |
| IBTO | -12.43% | $351.41M | 0.07% |
| IBTG | -12.03% | $1.92B | 0.07% |
| VGIT | -12.02% | $31.79B | 0.04% |
| SPTI | -11.85% | $8.80B | 0.03% |
| IEI | -11.82% | $15.41B | 0.15% |
| VGSH | -11.67% | $22.77B | 0.03% |
| IBTL | -11.41% | $379.97M | 0.07% |
| IBTK | -11.34% | $441.97M | 0.07% |
| FLGV | -11.28% | $1.01B | 0.09% |
| IBTM | -11.19% | $315.47M | 0.07% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CRDF | 41.46% | $233.51M | +68.75% | 0.00% |
| CLPT | 37.36% | $318.26M | +112.45% | 0.00% |
| CRNX | 34.50% | $2.66B | -37.57% | 0.00% |
| BEAM | 33.55% | $1.76B | -22.33% | 0.00% |
| IMVT | 33.11% | $2.76B | -39.10% | 0.00% |
| LGND | 33.04% | $2.17B | +32.75% | 0.00% |
| PUMP | 32.02% | $645.28M | -25.98% | 0.00% |
| ARLO | 31.70% | $1.77B | +30.54% | 0.00% |
| DYN | 31.22% | $986.63M | -74.95% | 0.00% |
| KYMR | 31.16% | $3.12B | +47.05% | 0.00% |
| AUPH | 30.05% | $1.01B | +37.75% | 0.00% |
| SEI | 29.51% | $1.17B | +240.91% | 1.66% |
| TSE | 29.50% | $108.73M | +48.06% | 1.29% |
| SNDX | 29.40% | $758.94M | -57.31% | 0.00% |
| BDTX | 29.07% | $141.02M | -41.09% | 0.00% |
| NRIX | 29.02% | $892.72M | -38.14% | 0.00% |
| OLLI | 28.61% | $8.00B | +32.71% | 0.00% |
| ACLX | 28.38% | $3.56B | +21.48% | 0.00% |
| GOOG | 28.12% | $2.15T | -5.20% | 0.46% |
| GOOGL | 28.12% | $2.13T | -5.07% | 0.46% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 31.04% | $4.84B | 0.35% |
| GNOM | 30.04% | $44.38M | 0.5% |
| RDTE | 28.57% | $137.58M | 0.97% |
| IWC | 25.87% | $817.74M | 0.6% |
| IBB | 25.73% | $5.28B | 0.45% |
| QTUM | 25.64% | $1.56B | 0.4% |
| ARKG | 25.18% | $1.02B | 0.75% |
| PBE | 24.15% | $223.86M | 0.58% |
| PTH | 24.03% | $100.70M | 0.6% |
| XLC | 23.33% | $23.84B | 0.09% |
| PINK | 23.04% | $129.96M | 0.5% |
| FCOM | 22.79% | $1.61B | 0.084% |
| VOX | 22.39% | $5.30B | 0.09% |
| KRE | 22.12% | $3.39B | 0.35% |
| XPH | 22.06% | $148.46M | 0.35% |
| KBWB | 21.93% | $4.62B | 0.35% |
| MAGS | 21.85% | $2.48B | 0.29% |
| KCE | 21.76% | $494.66M | 0.35% |
| IWO | 21.58% | $11.53B | 0.24% |
| VTWO | 21.57% | $12.58B | 0.07% |
Yahoo
uniQure N.V. (NASDAQ:QURE) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Lake Street Capital reiterated its Buy rating and $30 price target for ClearPoint following uniQure N.V. (NASDAQ:QURE) regulatory update on AMT-130, an experimental gene therapy for Huntington’s disease. uniQure N.V. (NASDAQ:QURE) declared that it has partnered with the FDA […]
SeekingAlpha
uniQure: Price And Value Have Caught Up
Finnhub
LEXINGTON, AMSTERDAM - uniQure N.V. , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced the appointment of Kylie O'Keefe as Chief...
Yahoo
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Kylie O’Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. In this role, Ms. O’Keefe will lead the development and execution of uniQure’s global commercial
Finnhub
uniQure N.V. announced the appointment of Kylie O?Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. In this role, Ms. O?Keefe will lead the development and execution of uniQure?s...
Finnhub
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 -- uniQure N.V. , a leading gene therapy company...
